PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab.

Abstract Septic arthritis represents 8-27% of cases of monoarthritis presenting to the emergency department. Tocilizumab is an interleukin-6 blocking monoclonal antibody with the mechanistic potential to interfere with the body's normal inflammatory response to an infectious insult. We present a case of septic arthritis with a normal white cell count, C-reactive protein, erythrocyte sedimentation rate and fibrinogen in a patient treated with tocilizumab.
PMID
Related Publications

Septic versus inflammatory arthritis: discriminating the ability of serum inflammatory markers.

A case of disseminated sporotrichosis treated with prednisolone, immunosuppressants, and tocilizumab under the diagnosis of rheumatoid arthritis.

Synovial fluid findings in children with knee monoarthritis in lyme disease endemic areas.

Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts.

Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction.

Authors

Mayor MeshTerms
Keywords

Interleukin-6

septic arthritis

tocilizumab

Journal Title clinical medicine (london, england)
Publication Year Start




PMID- 28572233
OWN - NLM
STAT- MEDLINE
DA  - 20170602
DCOM- 20170629
LR  - 20170629
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
VI  - 17
IP  - 3
DP  - 2017 Jun
TI  - Lesson of the month 1: Septic arthritis with normal acute phase reactants and
      white cell count in a patient receiving tocilizumab.
PG  - 280-281
LID - 10.7861/clinmedicine.17-3-280 [doi]
AB  - Septic arthritis represents 8-27% of cases of monoarthritis presenting to the
      emergency department. Tocilizumab is an interleukin-6 blocking monoclonal
      antibody with the mechanistic potential to interfere with the body's normal
      inflammatory response to an infectious insult. We present a case of septic
      arthritis with a normal white cell count, C-reactive protein, erythrocyte
      sedimentation rate and fibrinogen in a patient treated with tocilizumab.
CI  - (c) Royal College of Physicians 2017. All rights reserved.
FAU - Conway, Richard
AU  - Conway R
AD  - Mater Misericordiae University Hospital and CARD Newman Research Fellow,
      University College Dublin, Dublin, Ireland [email protected]
FAU - Orr, Carl
AU  - Orr C
AD  - Department of Rheumatology, Mater Misericordiae University Hospital, Dublin,
      Ireland.
FAU - McCarthy, Geraldine M
AU  - McCarthy GM
AD  - Department of Rheumatology, Mater Misericordiae University Hospital, Dublin,
      Ireland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use
MH  - Arthritis, Infectious/*diagnosis/*etiology
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Humans
MH  - Interleukin-6/blood
MH  - Knee/*pathology
MH  - Leukocyte Count
MH  - Male
OTO - NOTNLM
OT  - Interleukin-6
OT  - septic arthritis
OT  - tocilizumab
EDAT- 2017/06/03 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/03 06:00
AID - 17/3/280 [pii]
AID - 10.7861/clinmedicine.17-3-280 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2017 Jun;17(3):280-281. doi: 10.7861/clinmedicine.17-3-280.